Nanexa AB is a pharmaceutical company with a patented drug delivery platform－PharmaShell® using a coating technique called Atomic Layer Deposition (ALD). PharmaShell® consists of inorganic prolonged-release coatings which encloses API particles. It provides sustained release with high drug loads for small molecule APIs as well as biopharmaceuticals. PharmaShell® allows tailored depot lengths between one week and several months. The company has established cGMP manufacturing capabilities for production of clinical trials material.
Since its founding in 2007, Nanexa has based its operations on ALD. Over the years, Nanexa has utilized the ALD technology in a variety of projects and today, Nanexa runs two projects of its own, making long-acting injectable versions of important hematological cancer drugs—one of which is currently in clinical trials—as well as running partnering projects making long acting injectables of customer compounds.